Diamorphine infusion in the preterm neonate

A C Elias-Jones, D A Barrett, N Rutter, P N Shaw, S S Davis

Abstract
The effects of diamorphine were studied in 34 premature neonates who were given a loading dose of 50 μg/kg of diamorphine followed by a constant rate intravenous infusion of 15 μg/kg/hour. Small but significant falls were noted in blood pressure (at 30 minutes) and heart rate (at 30 minutes, six hours, and 12 hours) after administration of diamorphine, but these did not appear to cause any clinical deterioration and were thought to be related to the sedative effect of the drug. A significant fall in respiration rate at 30 and 60 minutes reflected the desired intention to encourage synchronisation of the infants' breathing with the ventilator. The mean (SD) plasma concentration of morphine measured during the infusion at steady state was 62.5 (22.8) ng/ml (range 20 to 98 ng/ml). The data suggest that this dosage regimen of diamorphine is safe. It results in plasma concentrations of morphine in the premature neonate which are comparable with those that are known to provide effective analgesia in the child and adult.

Until recently it was believed that newborn infants did not feel pain and consequently the use of analgesics in neonatal units was limited. It is now accepted that pain pathways are well developed in newborn babies and that an acute stress response to pain is readily detected as hormonal and metabolic changes. There is good evidence that the use of opioid analgesic infusions reduces this stress response in preterm infants undergoing surgery and as a result there is increasing use of opioids as analgesia in neonatal units. In addition, opioids are now being used more frequently as a sedative in mechanically ventilated newborn infants. This practice is believed to improve the synchronisation between the infant's own breathing and the ventilator. As well as these potentially beneficial effects, opioids do have unwanted side effects and care must be taken to ensure that the chosen dosage regimen does not cause unnecessary danger to the patient.

Diamorphine (3,6-diacetylmorphine) is a synthetic derivative of the opioid morphine. In man, diamorphine is rapidly metabolised to 6-acetylmorphine and morphine and it is generally accepted that diamorphine acts as a prodrug for its active metabolites. Diamorphine has been reported to be a faster acting and more potent analgesic than morphine, features thought to derive from its more rapid uptake into the brain due to its increased lipid solubility compared with morphine. In addition, the increased aqueous solubility of diamorphine compared with morphine is advantageous for intravenous administration. Diamorphine infusion is currently in use clinically to treat both mature and premature newborns, the diamorphine dosing regimen being based on that for morphine. This study was designed to evaluate the effect of diamorphine and to establish the safety of our current dose regimen in the premature neonate.

Patients and methods

Patients received a loading dose of diamorphine of 50 μg/kg given as an intravenous infusion over 30 minutes, followed by a continuous infusion at a rate of 15 μg/kg/hour. The loading dose and the continuous infusion rate were based on the lowest recommended doses for morphine administration, to take into account the reported higher potency of diamorphine compared with morphine. Diamorphine hydrochloride was diluted in 10% dextrose and infused at a rate of 0.5 ml/hour to keep the volume of fluid administered to a minimum. For clinical reasons certain patients received a different loading dose or infusion rate of diamorphine, and in some patients the infusion rate was changed during the study. The duration of the diamorphine infusion ranged from 14 to 149 hours (mean (SD) 59.4 (32.9) hours).

Observations were carried out on 34 infants, 20 of whom were studied closely in the first 24 hours after the loading dose of diamorphine, the remainder had normal regular nursing observations during the infusion and for 24 hours after the end of the infusion. In the closely studied group, measurements of mean blood pressure, heart rate, respiratory rate, temperature, arterial pH, oxygen tension (P(02)), carbon dioxide tension (P(CO2)), and blood glucose concentration were made before the loading dose of diamor-
phine and at 30 minutes, one, six, 12, and 24 hours after the dose.

**BLOOD SAMPLING AND ANALYSIS**

Arterial blood samples (0-5 ml) were collected after the loading dose, two to five times during the continuous infusion, and serially 10 times in the 24 hours after discontinuation of the diamorphine infusion. Plasma was separated and stored at -30°C until analysed. Plasma from eight subjects was analysed by a high pressure liquid chromatography (HPLC) method for morphine and 6-acetylmorphine.13 This HPLC method involved solid phase extraction, fluorescent derivatisation, and fluorescence detection of morphine and 6-acetylmorphine in plasma. The limit of quantitation for the assay was 10 ng/ml for morphine and 25 ng/ml for 6-acetylmorphine (0-1 ml plasma volume). The remaining samples were analysed by a Coat-A-Count radioimmunoassay (RIA) method (Diagnostic Products Ltd) which was highly specific for morphine. The RIA method showed low cross reactivity (<0.5%) with diamorphine, 6-acetylmorphine, and other metabolites of morphine. The steady state concentration was taken as the morphine plasma concentration at the end of the diamorphine infusion, or as a mean of values during infusion where these were within ±10% of each other. Good agreement was achieved between the RIA and HPLC methods. During the study, drugs other than diamorphine were administered to the infants, the most common being benzylpenicillin, gentamicin, flucloxacillin, metronidazole, and cefotaxime. There was no evidence that these drugs interfered with the assay for morphine in plasma.

**Results**

Table 1 shows the mean values compared with the predose values for heart rate, mean blood pressure, respiratory rate, blood pH, blood PCO₂, blood PCO₂, and blood glucose. Blood pressure showed a transient reduction at 30 minutes (p<0.03) which was not maintained at one, six, 12, or 24 hours. There was a significant fall (p<0.03) in heart rate at 30 minutes and at six and 12 hours but significant differences were not observed at 60 minutes, 12, or 24 hours. A significant fall (p<0.01) in respiratory rate was noted at both 30 and 60 minutes after infusion but this was not sustained later in the infusion. No significant differences were observed in arterial pH, PCO₂, Po₂, or in blood glucose for the duration of the study. Table 2 shows the mean percentage changes in heart rate, mean blood pressure, and respiratory rate in 20 preterm infants after diamorphine loading and infusion. Each value is mean (SD)

**Discussion**

Although small, significant falls in heart rate and mean blood pressure were noted during the diamorphine infusion, they were not associated with any clinical deterioration. They may have been related to the reduction of stress in the infants caused by the sedative and analgesic effects of the drug rather than being due to unwanted side effects. Although the mean blood pressure and heart rate of patients in the study are towards the limit of desirable values, they still fall within the normal range for premature infants.14 Similar but more appreciable reductions in heart rate and blood pressure have been noted by other workers studying opioid drugs, with particular concern if the dose was given as an intravenous bolus.34 The loading dose was given as a slow bolus over 30 minutes in our study, perhaps preventing any noticeable changes in these cardiovascular measurements.

The fall in respiration rate reflected the desired intention to settle the patients and encourage synchronisation of the infants' own efforts with the ventilator, which was achieved in 19 of the 20 babies studied by one hour after starting the diamorphine infusion. In this study direct measures of analgesic and sedative benefit were not made, although the subjects were noted to be more relaxed after the introduction

<table>
<thead>
<tr>
<th>Time from baseline measurement (hours)</th>
<th>% Change in heart rate</th>
<th>% Change in mean blood pressure</th>
<th>% Change in respiratory rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5</td>
<td>-2.3 (4.5)*</td>
<td>-6.3 (11.6)*</td>
<td>-6.6 (9.5)**</td>
</tr>
<tr>
<td>1</td>
<td>-2.0 (6.1)*</td>
<td>-4.5 (11.8)</td>
<td>-8.2 (12.0)**</td>
</tr>
<tr>
<td>6</td>
<td>-6.1 (5.9)**</td>
<td>-3.4 (16.3)</td>
<td>-1.7 (23.2)</td>
</tr>
<tr>
<td>12</td>
<td>-5.2 (8.3)*</td>
<td>-2.6 (17.2)</td>
<td>0.6 (30.4)</td>
</tr>
<tr>
<td>24</td>
<td>-4.2 (11.7)</td>
<td>4.3 (23.7)</td>
<td>5.0 (37.4)</td>
</tr>
</tbody>
</table>

Paired t test: p<0.05, **p<0.01.

**Table 2**

**Table 1**

<table>
<thead>
<tr>
<th>Time of measurement (hours after start)</th>
<th>Heart rate (beats/minute)</th>
<th>Mean blood pressure (mmHg)</th>
<th>Respiratory rate (breaths/minute)</th>
<th>pH</th>
<th>PaO₂ (kPa)</th>
<th>PaCO₂ (kPa)</th>
<th>Blood glucose (mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predose</td>
<td>152-4 (10-1)</td>
<td>38-8 (7-4)</td>
<td>75-3 (16-1)</td>
<td>7.20 (0-10)</td>
<td>7-1 (2-4)</td>
<td>6-5 (1-8)</td>
<td>4-3 (1-4)</td>
</tr>
<tr>
<td>0-5</td>
<td>146-9 (5-15)</td>
<td>36-5 (8-5)</td>
<td>70-3 (17-4)</td>
<td>7-22 (0-11)</td>
<td>6-9 (2-3)</td>
<td>6-6 (1-9)</td>
<td>4-2 (1-4)</td>
</tr>
<tr>
<td>1</td>
<td>149-8 (16-31)</td>
<td>37-1 (8-4)</td>
<td>68-9 (17-3)</td>
<td>7-22 (0-11)</td>
<td>7-1 (2-2)</td>
<td>5-8 (1-8)</td>
<td>4-3 (2-6)</td>
</tr>
<tr>
<td>6</td>
<td>144-2 (16-0)</td>
<td>37-2 (5-5)</td>
<td>72-0 (19-3)</td>
<td>7-21 (0-11)</td>
<td>8-4 (3-4)</td>
<td>6-5 (1-7)</td>
<td>4-7 (2-0)</td>
</tr>
<tr>
<td>12</td>
<td>144-0 (12-7)</td>
<td>37-6 (6-4)</td>
<td>70-8 (17-8)</td>
<td>7-24 (0-10)</td>
<td>7-8 (1-3)</td>
<td>6-8 (1-9)</td>
<td>4-2 (1-4)</td>
</tr>
<tr>
<td>24</td>
<td>144-2 (13-0)</td>
<td>40-3 (7-9)</td>
<td>72-8 (19-1)</td>
<td>7-22 (0-11)</td>
<td>8-0 (1-8)</td>
<td>7-2 (2-6)</td>
<td>3-7 (1-7)</td>
</tr>
</tbody>
</table>

*Significant difference from predose value (two tailed Student's t test, p<0.03).
of the diamorphine infusions. Similarly, exact measurements of urine and stool outputs were not made, although urine retention and constipation are described with opiates.

The range of plasma morphine concentrations of between 20 and 98 ng/ml (mean 62.5 ng/ml) compares with reported minimum concentrations required for effective analgesia in children and adults of between 20 and 65 ng/ml. Thus it appears that the diamorphine infusion rate of 15 µg/kg/hour used in the study produces an effective plasma concentration of morphine, although this does not necessarily imply effective analgesia. It is not known whether the reported therapeutic plasma concentrations of analgesics in children and adults apply to newborn infants nor whether there is an increased sensitivity to the side effects of opioid drugs. In addition, there is no information on the extent to which the active metabolite of diamorphine, 6-acetylmorphine, enhances the analgesic effect of the main active metabolite, morphine. In this study no 6-acetylmorphine was detected in plasma after diamorphine administration but this was probably a result of the limited sensitivity of the assay.

We are planning further investigations to clarify the relationship between plasma concentrations of the active diamorphine metabolites, morphine and 6-acetylmorphine, and the analgesic effect in the neonate. Morphine pharmacokinetics were examined in the present study and are reported elsewhere.17

Our study has shown that diamorphine can be safely given to preterm newborn infants as a combination of a slowly administered loading dose and a continuous infusion. It appeared to be effective, and resulted in plasma morphine concentration which in a child or adult would provide adequate analgesia.

The assistance of Dr D Shortland in the clinical aspects of the study is acknowledged. D A Barrett was funded by Ciba-Geigy (USA).

Diamorphine infusion in the preterm neonate.

A C Elias-Jones, D A Barrett, N Rutter, P N Shaw and S S Davis

Arch Dis Child 1991 66: 1155-1157
doi: 10.1136/adc.66.10_Spec_No.1155

Updated information and services can be found at:
http://adc.bmj.com/content/66/10_Spec_No/1155

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/